Management of Acute Myocardial Infarction During the COVID-19 Pandemic
A Consensus Statement from the Society of Cardiovascular Angiography and Interventions (SCAI), American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP) | There is an association between cardiovascular disease and COVID-19; however, the majority of patients presenting for ischemic heart disease may not be infected with COVID-19. Cardiovascular manifestations of COVID-19 are complex and include patients presenting with acute myocardial infarction (AMI), myocarditis simulating an ST-elevation myocardial infarction (STEMI), stress cardiomyopathy, non-ischemic cardiomyopathy, coronary spasm, or myocardial injury without a documented Type 1 or Type 2 AMI. In addition, the prevalence of COVID-19 in the U.S. is unknown due to the significant risk of asymptomatic transmission.Furthermore, patients with cardiovascular disease who develop COVID-19 are at higher risk for mortality. Learn more about providing a systematic approach to the management of AMI during the COVID-19 pandemic by accessing this document.